Outsourcing Boasts Growth
Outsourced manufacturing set to grow by 6.6 percent over the next four years, according to Results Healthcare
Results Healthcare have published a review of outsourced manufacturing in pharma and biotech – and the news is good for the sector (1). The headline figure is an expected growth figure of 6.6 percent – well above the expected global GDP growth. This, the authors claim, is driven by the strong growth of the overall pharmaceutical sector, as well as an increase in the amount of outsourced manufacturing work. Over the next four years, growth is expected to be dedicated to small molecules and commercial manufacturing supply. Here are some of the key findings.
Top five CMOs and CROs by EV/EBITDA multiples – EV/EBITDA ratio is a comparison of enterprise value and earnings before interest, taxes, depreciation and amortization.
Top five major investments in recent years:
- New HPAPI facility in Shanghai by WuXi in 2014.
- Expansion of existing capacity at UK HPAPI facility by DPx/Patheon in 2014.
- Fareva announcement of a €25-million investment in a recently acquired asset in La Vallé, France, to add HPAPI capable facilities in 2015.
- Fermion announcement in 2016 of a €30-million investment in its Hanko, Finland, facility which will add additional HPAPI capacity.
- Alcami due to open a new 500 m2 kilolab-scale facility during Q1 2017.
The total outsourced market has above GDP growth expectations at 6.6%, driven by the outsourcing trend and strong growth of the underlying pharma sector.
The outsourced manufacturing market grows ahead of pharmaceuticals, helped by increased outsourcing and outperforming sub-sectors (e.g., biologics).
Company strategy findings:
- Most western companies see themselves as differentiated players.
- One-stop-shop is a popular strategy pursued by the large players.
- In the atmosphere of consolidation, size has been a goal for acquisitions.
- M&A is not a strategy followed by all, linked to the peculiarities of private and family ownership.
- Results Healthcare, “Pharma & biotech 2017 Review of outsourced manufacturing”, (2016). Available at: bit.ly/2k3gppE. Last accessed February 28, 2017.
Over the course of my Biomedical Sciences degree it dawned on me that my goal of becoming a scientist didn’t quite mesh with my lack of affinity for lab work. Thinking on my decision to pursue biology rather than English at age 15 – despite an aptitude for the latter – I realized that science writing was a way to combine what I loved with what I was good at.
From there I set out to gather as much freelancing experience as I could, spending 2 years developing scientific content for International Innovation, before completing an MSc in Science Communication. After gaining invaluable experience in supporting the communications efforts of CERN and IN-PART, I joined Texere – where I am focused on producing consistently engaging, cutting-edge and innovative content for our specialist audiences around the world.
